ABSTRACT
Introduction Self-medication is defined as the use of a medication or product to treat, alleviate, or prevent a condition or symptom of an illness or to promote health. Self-management is increasingly used for dermatological diseases, especially chronic inflammatory skin diseases. Hence, it is crucial to be aware of its prevalence and the leading factors of its usage. Therefore, this study aims to estimate the prevalence of self-treatment for dermatological diseases and to determine possible factors associated with its practice. Methodology This is a cross-sectional online-based questionnaire study that was conducted in King Fahad Armed Forces Hospital in Jeddah, Saudi Arabia. In this study, we included all first-visit and follow-up patients diagnosed with vitiligo, eczema, alopecia areata, and psoriasis. Data analysis was conducted using JMP Statistical Discovery Software, version 15 (JMP Statistical Discovery LLC, Cary, NC). Results Of the 203 patients who participated in this study, 91 (44.8%) had vitiligo. Moreover, topical corticosteroids were the most commonly used medications in self-treatment and included mometasone and hydrocortisone, which were used by 143 (41.3%) and 50 (14.5%) patients, respectively. Thirty patients (16.2%) improved with self-treatment, whereas 52 (28.1%) had no improvement. In addition, the most common reason for self-treatment was having mild symptoms of the disease in 97 patients (30.1%). Conclusion This study revealed that the prevalence of self-treatment among various dermatological diseases was 53.2%. Topical corticosteroids were the most commonly used conventional medicines, whereas the most common alternative medications used were honey and henna. We found that the most common reason for self-treatment was mildness of the dermatological disease. Family and friends were the most common sources of information.
ABSTRACT
Cyclin-dependent kinase (CDK) 4 and 6 inhibitors, such as palbociclib, have emerged as essential in managing hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. While effective, these inhibitors can cause rare dermatologic side effects, including vitiligo-like depigmentation. We report a rare case of a 52-year-old female with HR+, HER2- metastatic breast cancer who developed vitiligo-like depigmentation following palbociclib treatment. The patient presented with asymptomatic depigmented lesions on the lower limbs and abdomen, appearing seven months after starting palbociclib. Examination and investigations confirmed the diagnosis after excluding other potential causes. Despite treatment with topical steroids and calcineurin inhibitors, there was no significant improvement, highlighting the need for more research into effective management strategies for drug-induced vitiligo. This case emphasizes the importance of recognizing rare dermatologic side effects of CDK4/6 inhibitors like palbociclib. Ongoing vigilance, reporting, and research are necessary to improve understanding and management of these side effects, ultimately enhancing patient care in oncology.
ABSTRACT
BACKGROUND: Minimally invasive sacroiliac joint (MISIJ) fusion is a surgical option to relieve SIJ pain. The aim of this systematic review and meta-analysis was to compare MISIJ fusion with triangular titanium implants (TTI) to nonoperative management of SIJ dysfunction. METHODS: We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. We included prospective clinical trials that compared MISIJ fusion to nonoperative management in individuals with chronic low back pain attributed to SIJ dysfunction. We evaluated pain on visual analogue scale, Oswestry Disability Index (ODI) score, health-related quality of life (HRQoL) using the 36-Item Short Form Health Survey (SF-36) physical component (PCS) and mental component summary (MCS) scores, patient satisfaction, and adverse events. RESULTS: A total of 8 articles representing 3 trials that enrolled 423 participants were deemed eligible. There was a significant reduction in pain score with MISIJ fusion compared with nonoperative management (standardized mean difference [SMD] -1.71, 95% confidence interval [CI] -2.03 to -1.39). Similarly, ODI scores (SMD -1.03, 95% CI -1.24 to -0.81), SF-36 PCS scores (SMD 1.01, 95% CI 0.83 to 1.19), SF-36 MCS scores (SMD 0.72, 95% CI 0.54 to 0.9), and patient satisfaction (odds ratio 6.87, 95% CI 3.73 to 12.64) were significantly improved with MISIJ fusion. No significant difference was found between the 2 groups with respect to adverse events (SMD -0.03, 95% CI -0.28 to 0.23). CONCLUSION: Our analysis showed that MISIJ fusion with TTI shows a clinically important and statistically significant improvement in pain, disability score, HRQoL, and patient satisfaction with a similar adverse event profile to nonoperative management in patients with chronic low back pain attributed to SIJ dysfunction.